

# Ramiro Garzon

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11964887/ramiro-garzon-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127  
papers

17,883  
citations

47  
h-index

131  
g-index

131  
ext. papers

19,376  
ext. citations

8.1  
avg, IF

6.21  
L-index

#	Paper	IF	Citations
127	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1793-801	59.2	2041
126	MicroRNAs in Cancer. <i>Annual Review of Medicine</i> , <b>2009</b> , 60, 167-79	17.4	1516
125	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 15805-10	11.5	1385
124	Targeting microRNAs in cancer: rationale, strategies and challenges. <i>Nature Reviews Drug Discovery</i> , <b>2010</b> , 9, 775-89	64.1	1143
123	A microRNA signature of hypoxia. <i>Molecular and Cellular Biology</i> , <b>2007</b> , 27, 1859-67	4.8	881
122	MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. <i>Blood</i> , <b>2009</b> , 113, 6411-8	2.2	655
121	MiR-15a and miR-16-1 cluster functions in human leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 5166-71	11.5	642
120	MicroRNA expression and function in cancer. <i>Trends in Molecular Medicine</i> , <b>2006</b> , 12, 580-7	11.5	615
119	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. <i>Blood</i> , <b>2008</b> , 111, 3183-9	2.2	536
118	NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. <i>Cancer Cell</i> , <b>2008</b> , 14, 369-81	24.3	496
117	MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 12885-90	11.5	467
116	Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 15676-84	5.4	450
115	miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. <i>Cell</i> , <b>2010</b> , 140, 652-65	56.2	427
114	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3945-50	11.5	426
113	Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 7473-8	11.5	399
112	MicroRNA expression in cytogenetically normal acute myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 1919-28	59.2	386
111	MicroRNA fingerprints during human megakaryocytopoiesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 5078-83	11.5	386

110	MicroRNA 29b functions in acute myeloid leukemia. <i>Blood</i> , <b>2009</b> , 114, 5331-41	2.2	379
109	Reprogramming of miRNA networks in cancer and leukemia. <i>Genome Research</i> , <b>2010</b> , 20, 589-99	9.7	287
108	The prognostic and functional role of microRNAs in acute myeloid leukemia. <i>Blood</i> , <b>2011</b> , 117, 1121-9	2.2	218
107	Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. <i>Cancer Cell</i> , <b>2010</b> , 17, 333-47	24.3	218
106	MicroRNAs in normal and malignant hematopoiesis. <i>Current Opinion in Hematology</i> , <b>2008</b> , 15, 352-8	3.3	197
105	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 18679-84	11.5	181
104	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 4144-57	15.9	170
103	Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 120, 1765-73	2.2	161
102	Acute Myeloid Leukemia: A Concise Review. <i>Journal of Clinical Medicine</i> , <b>2016</b> , 5,	5.1	161
101	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5257-64	2.2	155
100	CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 2395-407	15.9	147
99	Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2355-67	12.9	146
98	Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2086-93	2.2	141
97	Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. <i>Blood</i> , <b>2008</b> , 111, 2364-73	2.2	124
96	Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 548-56	2.2	119
95	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 119, 6025-31	2.2	119
94	Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. <i>Cancer Cell</i> , <b>2012</b> , 22, 645-55	24.3	115
93	Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. <i>Blood</i> , <b>2013</b> , 122, 3034-44	2.2	114

92	Regulation of acute graft-versus-host disease by microRNA-155. <i>Blood</i> , <b>2012</b> , 119, 4786-97	2.2	108
91	miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the EμmiR-155 transgenic mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 20047-52	11.5	103
90	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. <i>Blood</i> , <b>2017</b> , 129, 3175-3183	2.2	88
89	A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. <i>Blood</i> , <b>2017</b> , 129, 3165-3174	2.2	82
88	Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 1422-30	4.7	79
87	Dose escalation of lenalidomide in relapsed or refractory acute leukemias. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4919-25	2.2	73
86	MicroRNAs: emerging key regulators of hematopoiesis. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 935-42	4.1	73
85	Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. <i>Blood</i> , <b>2012</b> , 120, 2466-74	2.2	64
84	Potential of microRNAs for cancer diagnostics, prognostication and therapy. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 655-9	4.2	58
83	Lenalidomide-mediated enhanced translation of C/EBPβ30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. <i>Blood</i> , <b>2013</b> , 121, 159-69	2.2	53
82	XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIIα to the Nucleus. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 6142-6152	12.9	53
81	Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. <i>Cancer</i> , <b>2011</b> , 117, 4696-706	6.4	52
80	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. <i>Blood</i> , <b>2016</b> , 128, 1424-35	2.2	46
79	HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3537-49	12.9	45
78	Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , <b>2013</b> , 6, 21	22.4	42
77	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 1512-24	15.9	42
76	Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. <i>Blood</i> , <b>2014</b> , 123, 2412-5	2.2	40
75	Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 406-10	4.5	38

74	Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. <i>Seminars in Oncology</i> , <b>2011</b> , 38, 781-7	5.5	38
73	The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. <i>Nature Communications</i> , <b>2019</b> , 10, 5351	17.4	38
72	Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. <i>Blood</i> , <b>2015</b> , 125, 2689-92	2.2	37
71	Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2100-8	1.9	34
70	Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. <i>Leukemia</i> , <b>2019</b> , 33, 2169-2182	10.7	33
69	Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. <i>Journal of Immunology</i> , <b>2017</b> , 198, 2500-2512	5.3	32
68	A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. <i>Genome Medicine</i> , <b>2014</b> , 6, 76	14.4	29
67	Micro-RNA Expression and Function in Lymphomas. <i>Advances in Hematology</i> , <b>2011</b> , 2011, 347137	1.5	29
66	Knockout of both miR-15/16 loci induces acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 13069-13074	11.5	26
65	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E4641-E4647	11.5	25
64	Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	25
63	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , <b>2017</b> , 102, 1391-1400	6.6	23
62	Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity. <i>Molecular Pharmaceutics</i> , <b>2012</b> , 9, 1638-44	5.6	22
61	Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1304-8	1.9	21
60	MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. <i>Oncotarget</i> , <b>2016</b> , 7, 55395-55408	3.3	21
59	Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Of a First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2013</b> , 122, 90-90	2.2	19
58	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , <b>2020</b> , 1, 48-67	7	16
57	Clinical and functional significance of circular RNAs in cytogenetically normal AML. <i>Blood Advances</i> , <b>2020</b> , 4, 239-251	7.8	16

56	MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. <i>Journal of Immunology</i> , <b>2018</b> , 200, 4170-4179	5.3	15
55	PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	15
54	In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. <i>AAPS Journal</i> , <b>2013</b> , 15, 242-9	3.7	14
53	A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application. <i>AAPS Journal</i> , <b>2010</b> , 12, 556-68	3.7	14
52	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 340-349	4.3	13
51	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. <i>Hematological Oncology</i> , <b>2011</b> , 29, 202-10	1.3	12
50	Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 387-396	1.9	12
49	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. <i>Haematologica</i> , <b>2018</b> , 103, 982-987	6.6	11
48	Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. <i>Oncotarget</i> , <b>2018</b> , 9, 4354-4365	3.3	11
47	Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 608-618	12.9	10
46	Phase I study of AR-42 and decitabine in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1484-1492	1.9	9
45	The use of molecular genetics to refine prognosis in acute myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2014</b> , 9, 148-57	4.4	9
44	Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1036-51	24.4	8
43	Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 2831-2831	2.2	8
42	EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 669-678	12.9	8
41	Selinexor for advanced hematologic malignancies. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2335-2350	1.9	7
40	Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. <i>Haematologica</i> , <b>2020</b> , 105, 721-729	6.6	7
39	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 71-9	4.7	6

38	Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2561	8.4	5
37	HOXB-AS3 Regulates Cell Cycle Progression and Interacts with the Drosophila Splicing Human Behavior (DSHB) Complex in NPM1-Mutated Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 1514-1514	2.2	4
36	Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. <i>Blood Advances</i> , <b>2021</b> , 5, 1474-1482	7.8	4
35	ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. <i>Molecular Cell</i> , <b>2021</b> , 81, 2752-2764.e6	17.6	4
34	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. <i>Genome Research</i> , <b>2021</b> , 31, 747-761	9.7	4
33	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1451-1459	6.1	3
32	MicroRNAs in the diagnosis, prognosis and treatment of cancer. <i>Oncology Reviews</i> , <b>2008</b> , 2, 203-213	4.3	3
31	The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 3941-3941	2.2	3
30	A 17-Gene Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification. <i>Blood</i> , <b>2018</b> , 132, 289-289	2.2	2
29	Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance). <i>Blood</i> , <b>2020</b> , 136, 20-21	2.2	2
28	MiRNA-29b Targets MCL-1 and Is Down-Regulated in Chemotherapy-Resistant Acute Myeloid Leukemia (AML).. <i>Blood</i> , <b>2007</b> , 110, 717-717	2.2	2
27	Decitabine Priming Enhances The Antileukemic Effects Of The Selective Inhibitor Of Nuclear Export (SINE) CRM1/XPO1 Antagonist (Selinexor) In Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2013</b> , 122, 1453-1453 <sup>2,2</sup>	2.2	2
26	Clinical Implications of MicroRNAs in AML <b>2015</b> , 699-705		2
25	Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 107	22.4	2
24	Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine?. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 935-8	2.3	1
23	Serum Mir-29a Is Up-Regulated In Acute Graft Versus Host Disease (aGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) and Activates Dendritic Cells (DCs). <i>Blood</i> , <b>2013</b> , 122, 4471-4471	2.2	1
22	Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75. <i>Blood</i> , <b>2021</b> , 138, 4125-4125	2.2	1
21	Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity. <i>Blood</i> , <b>2016</b> , 128, 2909-2909	2.2	1

20	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1457-1465	7.1	1
19	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , <b>2021</b> ,	6.6	1
18	Clinical Applications of MicroRNAs in Acute Myeloid Leukemia: A Mini-Review. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 679022	5.3	1
17	Acute bulbar muscle dysfunction in hyperthyroidism. <i>Connecticut Medicine</i> , <b>2002</b> , 66, 3-6		1
16	Evidence of MicroRNA-29b and Sp1/NFB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.. <i>Blood</i> , <b>2009</b> , 114, 938-938	2.2	0
15	Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the gene. <i>Haematologica</i> , <b>2021</b> , 106, 2527-2532	6.6	0
14	MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host-Disease (aGVHD). <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, S58-S59	4.7	
13	MicroRNAs and Hematopoiesis <b>2013</b> , 91-100		
12	Implications of MicroRNAs in Normal Hematopoiesis and Human Leukemia. <i>Clinical Leukemia</i> , <b>2008</b> , 2, 96-101		
11	High throughput microRNAs profiling in cancers309-321		
10	Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 3300-3300	2.2	
9	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). <i>Blood</i> , <b>2018</b> , 132, 2767-2767	2.2	
8	Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD) <b>2019</b> , 2, 079-82		
7	EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , <b>2016</b> , 128, 2689-2689	2.2	
6	MicroRNA profiling of megakaryocytes. <i>Methods in Molecular Biology</i> , <b>2009</b> , 496, 293-8	1.4	
5	Regulation of Acute Graft-Versus-Host Disease by MicroRNA-155. <i>Blood</i> , <b>2010</b> , 116, 245-245	2.2	
4	Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results. <i>Blood</i> , <b>2012</b> , 120, 3616-3616	2.2	
3	A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2'ED-Methylphosphorothioate Mir-29b. <i>Blood</i> , <b>2013</b> , 122, 3933-3933	2.2	



- 2 Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity. *Blood*, **2013**, 122, 3966-3966 2.2
- 1 Methods Used to Make Lipid Nanoparticles to Deliver LNA Gapmers Against lncRNAs into Acute Myeloid Leukemia (AML) Blasts. *Methods in Molecular Biology*, **2021**, 2348, 167-174 1.4